MedWatch

Board on new Orphazyme CEO: He has the management style we want

Orphazyme's newly appointed CEO is of a different build than his predecessor, Kim Stratton, as his management style is more transparent and inclusive, according to Vice Chairman Bo Jesper Hansen, who is excited that the new top exec is moving to Denmark and already learning the language.

Orphazyme vice chairman Bo Jesper Hansen

"A scoop like no other."

This is how vice chairman at Orphazyme Bo Jesper Hansen describes the company board's successful endeavor to recruit Amgen's former Senior Vice president, General Manager, US Oncology Business Christophe Bourdon for the role of CEO for Orphazyme's around 150 employees.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs